Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $593924.0.

  • Immucell's Capital Expenditures rose 57176.85% to $593924.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 26321.45%. This contributed to the annual value of $465725.0 for FY2024, which is 7539.12% down from last year.
  • Per Immucell's latest filing, its Capital Expenditures stood at $593924.0 for Q3 2025, which was up 57176.85% from $155159.0 recorded in Q2 2025.
  • Over the past 5 years, Immucell's Capital Expenditures peaked at $1.5 million during Q4 2022, and registered a low of $70356.0 during Q1 2024.
  • Moreover, its 5-year median value for Capital Expenditures was $593924.0 (2025), whereas its average is $527383.9.
  • In the last 5 years, Immucell's Capital Expenditures crashed by 9454.13% in 2023 and then surged by 57176.85% in 2025.
  • Over the past 5 years, Immucell's Capital Expenditures (Quarter) stood at $704594.0 in 2021, then soared by 111.49% to $1.5 million in 2022, then crashed by 94.54% to $81344.0 in 2023, then skyrocketed by 141.22% to $196216.0 in 2024, then skyrocketed by 202.69% to $593924.0 in 2025.
  • Its Capital Expenditures was $593924.0 in Q3 2025, compared to $155159.0 in Q2 2025 and $329050.0 in Q1 2025.